Posted: 17/05/2022
This educational activity is intended for an international audience of pediatricians, primary care physicians and orthopedists
and orthopedic surgeons.
The goal of this activity is for the learner to be better able to better identify clinical manifestations of inborn errors
of metabolism, with a particular focus on mucopolysaccharidosis (MPS) IVA and IV and recognize the importance of implementing
early treatment in terms of patient outcomes.
Upon completion of this activity, participants will:
- Have increased knowledge regarding the
- Identification of clinical manifestations regarding the diffuse compromise of skeletal and nonskeletal structures
- Have greater competence related to
- Making a diagnosis early in the life of the patient to design the best treatment approach
Contents of This CPD Activity
All sections of this activity are required for credit.
Mucopolysaccharidoses: Classical and Nonclassical Patients
Global overview of newborn screening, with a focus on MPS, particularly MPS IVA and VI
Barbara K. Burton, MD
Clinical Case Scenarios: Differential Diagnosis of MPS vs Other Skeletal Dysplasia
Improve your ability to differentiate MPS IVA and MPS VI from other types of skeletal dysplasia
Klane K. White, MD, MSc
Mucopolysaccharidosis: The Importance of Early Treatment
Learn here about the impact of starting treatment early on patient outcomes
Martha Solano, MD
Mucopolysaccharidosis: Diagnostic Algorithm
Learn here all about diagnostic tools available, from classical to genetic panels
Roberto Giugliani, MD, PhD
Newborn Screening: What is it and How Will it Help the Diagnostic Journey?
Learn about recent developments about newborn screening and how this might impact management of MPS
Barbara K. Burton, MD